

# Jeffrey I Weitz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2918408/jeffrey-i-weitz-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

486 papers	48,203 citations	95 h-index	212 g-index
538 ext. papers	56,468 ext. citations	10.4 avg, IF	7.63 L-index

#	Paper	IF	Citations
486	Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI in Patients With ESRD.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 200-209	4.1	5
485	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery <b>2022</b> , 1,		2
484	Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions.. <i>Small</i> , <b>2022</b> , e2108112	11	1
483	Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. <i>Blood</i> , <b>2021</b> , 138, 3024-3024	2.2	
482	Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. <b>2021</b> , 3, e0588		1
481	Milvexian for the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 2161-2172	59.2	14
480	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1612-1620	11.5	81
479	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1684-1695	17	5
478	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1903-1921	15.1	84
477	Factor XI as a Target for New Anticoagulants. <i>Hamostaseologie</i> , <b>2021</b> , 41, 104-110	1.9	6
476	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , <b>2021</b> , 201, 63-72	8.2	3
475	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1546-1557	15.4	14
474	The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. <i>Blood</i> , <b>2021</b> , 138, 2173-2184	2.2	6
473	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. <i>Annals of Surgery</i> , <b>2021</b> , 274, e204-e211	7.8	10
472	New anticoagulants: Moving beyond the direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 20-29	15.4	15
471	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 157, 103125	7	1
470	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , <b>2021</b> , 5, e24-e34	3.4	6

469	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 308-313	5.1	2
468	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 326-341	5.1	3
467	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , <b>2021</b> , 203, 155-162	8.2	1
466	Abelacimab for Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 609-617	59.2	23
465	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2801-2813	15.4	1
464	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 625-631	15.1	10
463	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2772-2780	15.4	0
462	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 3008-3017	15.4	2
461	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 3080-3089	15.4	3
460	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1420-1429	8	7
459	Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. <i>Blood Advances</i> , <b>2021</b> , 5, 3540-3551	7.8	1
458	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , <b>2021</b> , 100, 1199-1207	9.9	2
457	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 3031-3043	15.4	1
456	Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. <i>ACS Biomaterials Science and Engineering</i> , <b>2021</b> , 7, 541-552	5.5	5
455	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1004-1024	7	147
454	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , <b>2020</b> , 136, 1433-1441	2.2	45
453	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 3140-3147	15.1	23
452	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 847-856	7	12

451	Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2364-2376	15.4	4
450	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1661-1671	15.4	6
449	Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , <b>2020</b> , 19, 333-352	64.1	82
448	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 267-277	5.1	15
447	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	16
446	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , <b>2020</b> , 17, 242-257	14.8	41
445	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 515-524	7	11
444	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 130-139	27.4	54
443	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , <b>2020</b> , 191, 103-112	8.2	10
442	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 1-11	5.1	3
441	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 20-29	5.1	7
440	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 12-19	5.1	3
439	The contact activation system as a potential therapeutic target in patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 500-505	5.1	24
438	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Blood</i> , <b>2020</b> , 136, 23-24	2.2	2
437	Recent advances in understanding, diagnosing and treating venous thrombosis. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	2
436	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , <b>2020</b> , 4, e446-e456	2.7	1
435	Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. <i>Journal of Trauma and Acute Care Surgery</i> , <b>2020</b> , 89, e177-e181	3.3	6
434	Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. <i>Annals of Thoracic Surgery</i> , <b>2020</b> , 110, 582-590	2.7	6

433	Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. <i>Biomaterials</i> , <b>2020</b> , 258, 120291	15.6	24
432	COVID-19 coagulopathy, thrombosis, and bleeding. <i>Blood</i> , <b>2020</b> , 136, 381-383	2.2	48
431	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2022886	10.4	5
430	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2950-2973	15.1	1682
429	Novel antithrombotic strategies for treatment of venous thromboembolism. <i>Blood</i> , <b>2020</b> , 135, 351-359	2.2	25
428	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1760-1768	15.1	12
427	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. <i>Circulation Research</i> , <b>2019</b> , 124, 416-425	15.7	22
426	Antithrombotic Agents. <i>Circulation Research</i> , <b>2019</b> , 124, 426-436	15.7	43
425	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". <i>Circulation Research</i> , <b>2019</b> , 124, e119	15.7	1
424	The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. <i>Acta Biomaterialia</i> , <b>2019</b> , 94, 2-10	10.8	66
423	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1694-1706	15.4	17
422	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1365-1372	7	18
421	Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 992-999	7	11
420	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , <b>2019</b> , 139, 2170-2185	16.7	49
419	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1825-1833	59.2	60
418	Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 981-991	7	14
417	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , <b>2019</b> , 104, e474-e477	6.6	0
416	Identification and characterization of a factor Va-binding site on human prothrombin fragment 2. <i>Scientific Reports</i> , <b>2019</b> , 9, 2436	4.9	4

415	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications <b>2019</b> , 1067-1077		
414	MAA868 locks factor XIa in a zymogen-like state. <i>Blood</i> , <b>2019</b> , 133, 1393-1394	2.2	5
413	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2019</b> , 13, 1753944719863641	3.4	3
412	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1675-1685	7	15
411	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2019</b> , 366, l4363	5.9	83
410	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1866-1874	15.4	23
409	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2019</b> , 3, 431-497	5.1	5
408	Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. <i>Thrombosis Research</i> , <b>2019</b> , 184, 44-49	8.2	6
407	Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. <i>ACS Biomaterials Science and Engineering</i> , <b>2019</b> , 5, 6485-6496	5.5	18
406	Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 2081-2088	15.4	4
405	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. <i>Blood</i> , <b>2019</b> , 134, 163-163	2.2	6
404	Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial. <i>Blood</i> , <b>2019</b> , 134, 3669-3669	2.2	
403	Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 689-694	7	9
402	Rivaroxaban for prevention and treatment of venous thromboembolism. <i>Future Cardiology</i> , <b>2019</b> , 15, 63-77	1.3	5
401	Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach <b>2019</b> , 1, e0032		11
400	Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. <i>Small</i> , <b>2019</b> , 15, e1905562	11	17
399	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 14-38	7	19
398	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 319-327	7	43



397	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 461-466	7	9
396	Advances in Antithrombotic Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 7-12	9.4	24
395	Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 413-417	15.4	6
394	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , <b>2018</b> , 131, 2151-2160	2.2	38
393	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , <b>2018</b> , 15, 273-281	14.8	92
392	2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 304-310	9.4	23
391	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , <b>2018</b> , 162, 7-14	8.2	18
390	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1001-1008	7	11
389	Global public awareness about atrial fibrillation. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 49-57	5.1	6
388	Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. <i>European Journal of Haematology</i> , <b>2018</b> , 101, 3-11	3.8	6
387	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, S23-S33	7	6
386	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , <b>2018</b> , 20, 1231-1242	3.9	148
385	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , <b>2018</b> , 39, 1330-1393	9.5	1094
384	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2018</b> , 27, 1673-1682	2.8	37
383	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , <b>2018</b> , 2, e1-e7	2.7	2
382	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. <i>Annals of Emergency Medicine</i> , <b>2018</b> , 71, 314-325.e1	2.1	28
381	Antithrombotic Drugs <b>2018</b> , 2168-2188		1
380	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1439-1449	7	98

379	Hematologic Problems in the Surgical Patient: Bleeding and Thrombosis <b>2018</b> , 2304-2312.e4		2
378	Overview of Hemostasis and Thrombosis <b>2018</b> , 1831-1842		4
377	Conductive Electrochemically Active Lubricant-Infused Nanostructured Surfaces Attenuate Coagulation and Enable Friction-Less Droplet Manipulation. <i>Advanced Materials Interfaces</i> , <b>2018</b> , 5, 1800617	4.6	32
376	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , <b>2018</b> , 168, 121-129	8.2	10
375	Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e003998	5.8	20
374	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , <b>2018</b> , 170, 75-83	8.2	4
373	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1118-1127	59.2	143
372	Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1116-1119	3.8	4
371	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , <b>2018</b> , 132, 2527-2527	2.2	1
370	Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thromboprophylaxis. <i>Blood</i> , <b>2018</b> , 132, 1236-1236	2.2	
369	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 615-624	59.2	806
368	Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 2338-2344	9.4	9
367	Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. <i>ACS Nano</i> , <b>2018</b> , 12, 10890-10902	16.7	54
366	Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. <i>Blood Advances</i> , <b>2018</b> , 2, 1806	7.8	1
365	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , <b>2018</b> , 2, 788-796	7.8	46
364	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , <b>2018</b> , 2, 3193-3195	7.8	
363	Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. <i>TH Open</i> , <b>2018</b> , 2, e190-e201	2.7	8
362	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2191-2201	59.2	432



361	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 1-6	2.5	4
360	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2018</b> , 138, 1963-1973	16.7	23
359	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD study. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 435-442	2.4	6
358	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematology</i> , <b>2017</b> , 4, e105-e113	14.6	67
357	Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2017</b> , 38, 40-50	3.9	13
356	Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. <i>Stroke</i> , <b>2017</b> , 48, 1432-1437	14.37	51
355	Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2491-2492	59.2	2
354	Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. <i>Scientific Reports</i> , <b>2017</b> , 7, 2102	4.9	28
353	Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex. <i>Biochemistry</i> , <b>2017</b> , 56, 3119-3128	3.2	6
352	Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply. <i>Lancet Haematology</i> , <b>2017</b> , 4, e254-e255	14.6	
351	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 566-574	16.2	72
350	Platelet polyphosphate: the long and the short of it. <i>Blood</i> , <b>2017</b> , 129, 1574-1575	2.2	14
349	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1211-1222	59.2	397
348	Emerging anticoagulant strategies. <i>Blood</i> , <b>2017</b> , 129, 147-154	2.2	44
347	Dabigatran Reversal with Idarucizumab. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1691-2	59.2	18
346	A Test in Context: D-Dimer. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2411-2420	15.1	173
345	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 2377-2387	15.4	15
344	Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. <i>F1000Research</i> , <b>2017</b> , 6, 985	3.6	17

343	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1509-1517	7	2
342	An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces. <i>Scientific Reports</i> , <b>2017</b> , 7, 11639	4.9	60
341	- a new ISTH publishing platform for the global thrombosis and hemostasis community. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2017</b> , 1, 6-8	5.1	
340	In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, JC17	8	
339	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 431-441	59.2	639
338	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , <b>2017</b> , 149, 29-37	8.2	10
337	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2406-2414	7	7
336	New developments in anticoagulants: Past, present and future. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1283-1288	7	58
335	Factors XI and XII as Targets for New Anticoagulants. <i>Frontiers in Medicine</i> , <b>2017</b> , 4, 19	4.9	46
334	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". <i>Circulation</i> , <b>2016</b> , 134, e498	16.7	
333	Urgent Need to Measure Effects of Direct Oral Anticoagulants. <i>Circulation</i> , <b>2016</b> , 134, 186-8	16.7	34
332	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. <i>American Journal of Gastroenterology Supplements (Print)</i> , <b>2016</b> , 3, 29-35		2
331	A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 241-50	7	6
330	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 747-53	7	21
329	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , <b>2016</b> , 144, 158-64	8.2	4
328	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , <b>2016</b> , 54, 644-6	2.9	29
327	Letter to the Editor: Managing Dabigatran-Related Bleeding. <i>Journal of Intensive Care Medicine</i> , <b>2016</b> , 31, 70-1	3.3	
326	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , <b>2016</b> , 3, e228-36	14.6	41

325	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1332-1339	3.8	5
324	Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157471	3.7	8
323	Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. <i>Polish Archives of Internal Medicine</i> , <b>2016</b> , 126, 688-696	1.9	9
322	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 257-70	7	11
321	Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 533-42	7	20
320	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 809-16	7	13
319	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 685-711	7	21
318	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, S33-S40	7	7
317	Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 89-98	7	33
316	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 1159-1164	7	14
315	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 1240-8	7	52
314	Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 1172-1179	7	36
313	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , <b>2016</b> , 1, 146-154	5.6	65
312	Prosthetic Heart Valve Thrombosis. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2670-2689	15.1	212
311	A PoTENTIAL Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants. <i>Circulation Research</i> , <b>2016</b> , 119, 1157-1160	15.7	3
310	Factor XI and factor XII as targets for new anticoagulants. <i>Thrombosis Research</i> , <b>2016</b> , 141 Suppl 2, S40-S58.2		46
309	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , <b>2016</b> , 129, S1-S29	2.4	19
308	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. <i>Circulation Research</i> , <b>2016</b> , 118, 1409-24	15.7	76

307	NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. <i>American Heart Journal</i> , <b>2016</b> , 177, 74-86	4.9	34
306	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , <b>2016</b> , 3, e437-45	14.6	23
305	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematology</i> , <b>2016</b> , 3, e379-87	14.6	93
304	Anticoagulation therapy in 2015: where we are and where we are going. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 39, 264-72	5.1	10
303	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 511-20	59.2	1223
302	Factor XI antisense oligonucleotide for venous thrombosis. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1672	59.2	13
301	Overview of the new oral anticoagulants: opportunities and challenges. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 1056-65	9.4	124
300	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15006	51.1	127
299	Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 2544-53	9.4	99
298	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 2506-2515	14.4	106
297	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e002322	6	60
296	Factor XI antisense oligonucleotide for prevention of venous thrombosis. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 232-40	59.2	358
295	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). <i>Thrombosis Research</i> , <b>2015</b> , 136 Suppl 1, S13-8	8.2	4
294	Medical device-induced thrombosis: what causes it and how can we prevent it?. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13 Suppl 1, S72-81	15.4	240
293	Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. <i>Blood</i> , <b>2015</b> , 125, 2712-22	9.2	30
292	Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 2187-91	15.4	126
291	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 645-50	7	40
290	Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1268-76	7	71

289	Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 1278-88	7	15
288	Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. <i>Shock</i> , <b>2015</b> , 44, 166-72	3.4	64
287	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1113-26	7	52
286	Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. <i>Chest</i> , <b>2015</b> , 148, 587-595	5.3	11
285	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 198-205	7	119
284	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , <b>2015</b> , 169, 751-7	4.9	62
283	Idarucizumab: The Antidote for Reversal of Dabigatran. <i>Circulation</i> , <b>2015</b> , 132, 2412-22	16.7	125
282	Abstract 17392: Gastrointestinal Bleeding With Edoxaban versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2015</b> , 132,	16.7	4
281	Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. <i>Blood</i> , <b>2014</b> , 123, 2102-7	2.2	106
280	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , <b>2014</b> , 383, 955-62	40	2823
279	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , <b>2014</b> , 124, 689-99	2.2	26
278	Thrombosis: a major contributor to global disease burden. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 2363-71	9.4	377
277	Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 1977-84	9.4	289
276	The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. <i>Circulation</i> , <b>2014</b> , 130, 1636-61	16.7	331
275	Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 924-31	7	29
274	Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. <i>Chest</i> , <b>2014</b> , 145, 1177-1178	5.3	15
273	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 1141-52	7	23
272	Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 412-8	7	17

271	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 79-86	7	11
270	Reduced plasminogen binding and delayed activation render D-fibrin more resistant to lysis than A-fibrin. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 27494-503	5.4	8
269	Thrombosis: a major contributor to global disease burden. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2014</b> , 40, 724-35	5.3	75
268	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. <i>Blood</i> , <b>2014</b> , 124, 1020-8	2.2	95
267	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 1428-36	15.4	155
266	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , <b>2014</b> , 28, 1791-6	3.5	18
265	Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. <i>Circulation</i> , <b>2014</b> , 129, 1688-94	16.7	20
264	Plasma fibronectin supports hemostasis and regulates thrombosis. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 4281-93	15.9	108
263	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. <i>Blood</i> , <b>2014</b> , 124, 1543-1543	2.2	3
262	Expanding use of new oral anticoagulants. <i>F1000prime Reports</i> , <b>2014</b> , 6, 93		15
261	The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. <i>BMC Biochemistry</i> , <b>2013</b> , 14, 6	4.8	5
260	Genetics of coagulation: what the cardiologist needs to know. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 75-88	3.8	4
259	Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, 93-100	8	60
258	Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2013</b> , 33, 2674-81	9.4	11
257	Strain history dependence of the nonlinear stress response of fibrin and collagen networks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 12197-202	11.5	176
256	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2093-104	59.2	3215
255	Zn <sup>2+</sup> mediates high affinity binding of heparin to the $\alpha$ domain of fibrinogen. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 29394-402	5.4	15
254	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 295-301	5.1	53



253	Apixaban for extended treatment of venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 699-708	59.2	882
252	General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 569-79	7	134
251	Procoagulants for management of bleeding with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1	7	1
250	Novel oral anticoagulants in gastroenterology practice. <i>Gastrointestinal Endoscopy</i> , <b>2013</b> , 78, 227-39	5.2	71
249	Oral apixaban for the treatment of acute venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 799-808	59.2	1495
248	The real decoy: an antidote for factor Xa-directed anticoagulants. <i>Circulation Research</i> , <b>2013</b> , 113, 954-7	15.7	17
247	Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 16862-16871	5.4	23
246	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 769-86	7	31
245	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1087-107	7	278
244	Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 205-12	7	121
243	Venous Thrombosis <b>2013</b> , 619-626		
242	Zinc: an important cofactor in haemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 421-30	30	57
241	Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. <i>Blood</i> , <b>2013</b> , 122, 211-211	2.2	13
240	Extended treatment of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , <b>2013</b> , 11, 302-4	0.6	
239	Dual surface modification with PEG and corn trypsin inhibitor: effect of PEG:CTI ratio on protein resistance and anticoagulant properties. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2012</b> , 100, 856-62	5.4	10
238	New oral anticoagulants: a view from the laboratory. <i>American Journal of Hematology</i> , <b>2012</b> , 87 Suppl 1, S133-6	7.1	28
237	Idrabiotaparinux treatment for venous thromboembolism. <i>Lancet, The</i> , <b>2012</b> , 379, 96-8	40	1
236	Translational success stories: development of direct thrombin inhibitors. <i>Circulation Research</i> , <b>2012</b> , 111, 920-9	15.7	50

235	Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. <i>Critical Care</i> , <b>2012</b> , 16, R151	10.8	164
234	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2012</b> , 144, 944-950.e3	1.5	12
233	By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin. <i>Biochemistry</i> , <b>2012</b> , 51, 7964-73	3.2	11
232	Oral direct factor Xa inhibitors. <i>Circulation Research</i> , <b>2012</b> , 111, 1069-78	15.7	78
231	Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. <i>Acta Biomaterialia</i> , <b>2012</b> , 8, 4092-100	10.8	58
230	A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 4652-61	5.4	27
229	Anticoagulation therapy. Dabigatran and risk of myocardial infarction. <i>Nature Reviews Cardiology</i> , <b>2012</b> , 9, 260-2	14.8	23
228	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1413-25	15.1	211
227	Modification of polyurethane with polyethylene glycol-corn trypsin inhibitor for inhibition of factor Xlla in blood contact. <i>Journal of Biomaterials Science, Polymer Edition</i> , <b>2012</b> , 23, 1981-93	3.5	8
226	New oral anticoagulants: which one should my patient use?. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 536-540	3.1	30
225	Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e89S-e119S	5.3	262
224	Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e24S-e43S	5.3	651
223	More on acutely injured patients receiving dabigatran. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 863; author reply 864	59.2	5
222	Periprocedural management and approach to bleeding in patients taking dabigatran. <i>Circulation</i> , <b>2012</b> , 126, 2428-32	16.7	95
221	New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e120S-e151S	5.3	170
220	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. <i>Blood</i> , <b>2012</b> , 120, LBA-1-LBA-1	2.2	4
219	New oral anticoagulants: which one should my patient use?. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 536-40	3.1	7
218	Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma chain. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 30314-30323	5.4	23

217	Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2167-77	59.2	423
216	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , <b>2011</b> , 127 Suppl 2, S5-S12	8.2	57
215	Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. <i>Blood</i> , <b>2011</b> , 117, 4134-41	2.2	37
214	Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. <i>Acta Biomaterialia</i> , <b>2011</b> , 7, 4177-86	10.8	18
213	Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. <i>Blood</i> , <b>2011</b> , 118, 6667-74	2.2	71
212	Hypercoagulable states. <i>Critical Care Clinics</i> , <b>2011</b> , 27, 933-52, vii	4.5	42
211	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ, The</i> , <b>2011</b> , 342, c7270	5.9	10
210	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 481-3	7	4
209	A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 1150-7	7	29
208	New anticoagulants. <i>Circulation</i> , <b>2010</b> , 121, 1523-32	16.7	227
207	Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 28912-23	5.4	35
206	HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 83-93	7	24
205	New oral anticoagulants in development. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 103, 62-70	7	93
204	Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. <i>Thrombosis Research</i> , <b>2010</b> , 126, e383-8	8.2	13
203	Potential of new anticoagulants in patients with cancer. <i>Thrombosis Research</i> , <b>2010</b> , 125 Suppl 2, S30-5	8.2	14
202	Role of the tissue factor pathway in the biology of tumor initiating cells. <i>Thrombosis Research</i> , <b>2010</b> , 125 Suppl 2, S44-50	8.2	36
201	Hypercoagulable states. <i>Clinics in Chest Medicine</i> , <b>2010</b> , 31, 659-73	5.3	27
200	Assays for measuring rivaroxaban: their suitability and limitations. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 673-9	3.2	128

199	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 633-41	7	263
198	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 642-9	7	126
197	New and emerging anticoagulant therapies for venous thromboembolism. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2010</b> , 12, 142-55	2.1	5
196	Update on heparin: what do we need to know?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 29, 199-207	3.1	46
195	Meeting the unmet needs in anticoagulant therapy. <i>European Journal of Haematology</i> , <b>2010</b> , 85, 1-28	3.8	61
194	Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 1212-8	7	7
193	Anticoagulation for ST-segment elevation myocardial infarction. <i>Circulation</i> , <b>2009</b> , 119, 1186-8	16.7	4
192	Long range communication between exosites 1 and 2 modulates thrombin function. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 25620-9	5.4	51
191	G-protein-coupled receptors as signaling targets for antiplatelet therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 449-57	9.4	90
190	Prevention and treatment of venous thromboembolism during pregnancy. <i>Catheterization and Cardiovascular Interventions</i> , <b>2009</b> , 74 Suppl 1, S22-6	2.7	1
189	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 28, 366-80	5.1	21
188	Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 1-22	6.2	404
187	Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 863-9	9.4	83
186	Unanswered questions in venous thromboembolism. <i>Thrombosis Research</i> , <b>2009</b> , 123 Suppl 4, S2-S10	8.2	13
185	Otamixaban in acute coronary syndromes. <i>Lancet, The</i> , <b>2009</b> , 374, 762-4	40	7
184	Dabigatran etexilate for prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 2-4	7	20
183	Overview of New Anticoagulant Drugs. <i>Fundamental and Clinical Cardiology</i> , <b>2009</b> , 133-154		
182	Selective factor Xa inhibition for thromboprophylaxis. <i>Lancet, The</i> , <b>2008</b> , 372, 6-8	40	7

181	New anticoagulants for treatment of venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 380-6	9.4	142
180	Contribution of host-derived tissue factor to tumor neovascularization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 1975-81	9.4	71
179	Bivalent binding to gammaA/gammaGfibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 2470-7	5.4	45
178	Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 141S-159S	5.3	560
177	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. <i>Blood</i> , <b>2008</b> , 112, 4432-6	2.2	76
176	New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 234S-256S	5.3	186
175	Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 100, 1058-1067	7	28
174	Inhibition of osteolytic bone metastasis by unfractionated heparin. <i>Clinical and Experimental Metastasis</i> , <b>2008</b> , 25, 903-11	4.7	8
173	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. <i>Blood</i> , <b>2008</b> , 112, 33-33	2.2	11
172	Laboratory assessment of platelet function and coagulation <b>2008</b> , 19-31		
171	In the presence of phospholipids, glycosaminoglycans potentiate factor Xa-mediated protein C activation by modulating factor Xa activity. <i>Biochemistry</i> , <b>2007</b> , 46, 4195-203	3.2	5
170	Beyond heparin and warfarin: the new generation of anticoagulants. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 271-82	5.9	57
169	A replacement for warfarin: the search continues. <i>Circulation</i> , <b>2007</b> , 116, 131-3	16.7	36
168	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , <b>2007</b> , 28, 880-913	9.13	94
167	Emerging Anticoagulant Drugs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 721-721	9.4	0
166	Zinc Enhances the Protection of Fibrin-Bound Thrombin from Antithro Inhibition.. <i>Blood</i> , <b>2007</b> , 110, 2691-2691	2.691	0
165	HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 37477-85	5.4	48
164	Changing paradigms in the management of venous thromboembolism. <i>The American Heart Hospital Journal</i> , <b>2006</b> , 4, 135-41		

163	Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 20780-20787	5.4	16
162	Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin. <i>Biochemistry</i> , <b>2006</b> , 45, 4257-65	3.2	10
161	A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 802-806	7	13
160	Emerging anticoagulants for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 274-84	7	80
159	Initial treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 242-50	7	9
158	OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2006</b> , 3, 478-9		1
157	An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2006</b> , 144, 812-21	8	113
156	The status of new anticoagulants. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 3-19	4.5	81
155	Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.. <i>Blood</i> , <b>2006</b> , 108, 193-193	2.2	
154	Emerging therapies for stroke prevention in atrial fibrillation. <i>Country Review Ukraine</i> , <b>2005</b> , 7, C19-C27		3
153	New anticoagulant therapy. <i>Annual Review of Medicine</i> , <b>2005</b> , 56, 63-77	17.4	27
152	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. <i>Blood</i> , <b>2005</b> , 105, 1734-41	2.2	444
151	New anticoagulants. <i>Blood</i> , <b>2005</b> , 105, 453-63	2.2	136
150	New anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 1843-53	15.4	153
149	New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. <i>British Journal of Pharmacology</i> , <b>2005</b> , 144, 1017-28	8.6	35
148	Pharmacology and clinical potential of direct thrombin inhibitors. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 3877-84	3.3	21
147	Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. <i>Circulation</i> , <b>2005</b> , 111, 1390-7	16.7	96
146	Coagulation assays. <i>Circulation</i> , <b>2005</b> , 112, e53-60	16.7	144



145	Zinc <sup>2+</sup> Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.. <i>Blood</i> , <b>2005</b> , 106, 1956-1956	2.2	
144	Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.. <i>Blood</i> , <b>2005</b> , 106, 1950-1950	2.2	
143	Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 1090-6	7	76
142	Localization of heparin and low-molecular-weight heparin in the rat kidney. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 927-34	7	6
141	Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2004</b> , 30, 21-30	5.3	46
140	New anticoagulants for treatment of venous thromboembolism. <i>Circulation</i> , <b>2004</b> , 110, 119-26	16.7	42
139	Ximelagatran: the first oral direct thrombin inhibitor. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 403-13	5.9	20
138	Management of venous thromboembolism: present and future. <i>Circulation</i> , <b>2004</b> , 110, 12	16.7	
137	Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 743-9	15.4	108
136	Modes and consequences of thrombin $\alpha$ interaction with fibrin. <i>Biophysical Chemistry</i> , <b>2004</b> , 112, 277-84	3.5	15
135	Thrombophilia and new anticoagulant drugs. <i>Hematology American Society of Hematology Education Program</i> , <b>2004</b> , 2004, 424-38	3.1	29
134	Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 576S-599S	5.3	181
133	Patients with severe sepsis vary markedly in their ability to generate activated protein C. <i>Blood</i> , <b>2004</b> , 104, 3958-64	2.2	131
132	New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 265S-286S	5.3	108
131	Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.. <i>Blood</i> , <b>2004</b> , 104, 1721-1721	2.2	
130	Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa.. <i>Blood</i> , <b>2004</b> , 104, 1724-1724	2.2	
129	No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model.. <i>Blood</i> , <b>2004</b> , 104, 2979-2979	2.2	
128	Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.. <i>Blood</i> , <b>2004</b> , 104, 1737-1737	2.2	

127	Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. <i>Circulation Research</i> , <b>2003</b> , 93, 1120-6	15.7	26
126	Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 23398-409	5.4	18
125	Emerging anticoagulant drugs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 1491-500	9.4	21
124	New anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2003</b> , 29, 619-31	5.3	18
123	A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. <i>Annals of Internal Medicine</i> , <b>2003</b> , 138, 787-94	8	90
122	Neutrophils and the protein C pathway. <i>Blood</i> , <b>2003</b> , 102, 1152-1153	2.2	1
121	Direct thrombin inhibitors in cardiac disease. <i>Cardiovascular Toxicology</i> , <b>2003</b> , 3, 13-25	3.4	24
120	Glycosaminoglycans bind factor Xa in a Ca <sup>2+</sup> -dependent fashion and modulate its catalytic activity. <i>Biochemistry</i> , <b>2003</b> , 42, 13091-8	3.2	9
119	A novel approach to thrombin inhibition. <i>Thrombosis Research</i> , <b>2003</b> , 109 Suppl 1, S17-22	8.2	45
118	Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. <i>Nuclear Medicine and Biology</i> , <b>2003</b> , 30, 61-72	2.1	33
117	Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 631-9	59.2	609
116	New anticoagulants: current status and future potential. <i>American Journal of Cardiovascular Drugs</i> , <b>2003</b> , 3, 201-9	4	23
115	Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 35767-74	5.4	34
114	Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 21584-91	5.4	56
113	Heparin and angiogenesis: size matters!. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 1954-5	9.4	18
112	Heparan sulfate: Antithrombotic or not?. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 952-954	15.9	32
111	Heparan sulfate: antithrombotic or not?. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 952-4	15.9	9
110	Thromboprophylaxis in surgical patients. <i>Canadian Journal of Surgery</i> , <b>2003</b> , 46, 129-35	2	39

109	Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin. <i>Trends in Cardiovascular Medicine</i> , <b>2002</b> , 12, 281-7	6.9	5
108	Direct thrombin inhibitors in acute coronary syndromes: present and future. <i>Circulation</i> , <b>2002</b> , 105, 1004-11	16.7	109
107	Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 7529-39	5.4	90
106	Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma C fibrinogen. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 7520-8	5.4	59
105	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. <i>Circulation</i> , <b>2002</b> , 105, 1650-5	16.7	907
104	The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. <i>Journal of Experimental Medicine</i> , <b>2002</b> , 196, 565-77	16.6	287
103	Identification of Dp71 isoforms in the platelet membrane cytoskeleton. Potential role in thrombin-mediated platelet adhesion. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 47106-13	5.4	22
102	Antithrombin-heparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention. <i>Circulation</i> , <b>2002</b> , 106, 261-5	16.7	30
101	Direct thrombin inhibitors. <i>Thrombosis Research</i> , <b>2002</b> , 106, V275-84	8.2	115
100	In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. <i>Thrombosis Research</i> , <b>2002</b> , 107, 241-4	8.2	60
99	Low-dose warfarin in rehabilitating stroke survivors. <i>Thrombosis Research</i> , <b>2002</b> , 107, 287-90	8.2	15
98	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. <i>Lancet, The</i> , <b>2002</b> , 359, 294-302	40	209
97	Acute coronary syndromes: a focus on thrombin. <i>Journal of Invasive Cardiology</i> , <b>2002</b> , 14 Suppl B, 2B-7B	0.7	3
96	Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. <i>Annals of Internal Medicine</i> , <b>2001</b> , 135, 108-11	8	128
95	New anticoagulant drugs. <i>Chest</i> , <b>2001</b> , 119, 95S-107S	5.3	119
94	New anticoagulant drugs. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2001</b> , 12, 7-17	5.1	3
93	Characterization of a mouse model for thrombomodulin deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2001</b> , 21, 1531-7	9.4	126
92	Antithrombotic therapy in patients undergoing percutaneous coronary intervention. <i>Chest</i> , <b>2001</b> , 119, 321S-336S	5.3	71

91	Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 385-91		51
90	Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 20959-65	5.4	81
89	Conformational changes in thrombin when complexed by serpins. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 44828-34	5.4	24
88	Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 9755-61	5.4	20
87	Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. <i>Circulation</i> , <b>2001</b> , 103, 643-50	16.7	40
86	Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). <i>American Heart Journal</i> , <b>2001</b> , 142, 237-43	4.9	8
85	Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 390-394	7	63
84	Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. <i>Archives of Internal Medicine</i> , <b>2000</b> , 160, 749-58		28
83	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 83, 416-420	7	1098
82	Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 19788-94	5.4	54
81	Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 36612-20	5.4	17
80	Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1439-44	59.2	336
79	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , <b>2000</b> , 266-284	3.1	17
78	Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 10112-20	5.4	47
77	The Asp(272)-Glu(282) region of platelet glycoprotein Ibalph interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 3887-95	5.4	50
76	Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. <i>Nuclear Medicine and Biology</i> , <b>2000</b> , 27, 289-97	2.1	108
75	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet, The</i> , <b>2000</b> , 355, 1936-42	40	343
74	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , <b>2000</b> , 2000, 266-284	3.1	2

73	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , <b>2000</b> , 2000, 266-284	3.1	
72	Mechanism of Action of Plasminogen Activators. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 974-982	7	33
71	Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development. <i>Blood</i> , <b>1999</b> , 93, 3442-3450	2.2	35
70	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , <b>1999</b> , 93, 1231-1236	2.2	60
69	Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. <i>Blood</i> , <b>1999</b> , 94, 959-967	2.2	292
68	Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 6226-33	5.4	62
67	Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 27597-604	5.4	45
66	Vasoflux, a new anticoagulant with a novel mechanism of action. <i>Circulation</i> , <b>1999</b> , 99, 682-9	16.7	31
65	Deep Vein Thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>1999</b> , 1, 43-54	2.1	1
64	New antithrombotic agents. <i>Lancet, The</i> , <b>1999</b> , 353, 1431-6	40	100
63	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 901-7	59.2	876
62	Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 417-23	8	82
61	New antithrombotic drugs: beyond aspirin and heparin. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1999</b> , 29 Suppl S1, 68		
60	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , <b>1999</b> , 93, 1231-1236	2.2	
59	Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. <i>American Journal of Cardiology</i> , <b>1998</b> , 82, 12P-18P	3	89
58	Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. <i>Translational Research</i> , <b>1998</b> , 132, 181-5		20
57	A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. <i>Journal of Internal Medicine</i> , <b>1998</b> , 243, 15-23	10.8	89
56	Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 18292-9	5.4	32

55	Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. <i>Circulation</i> , <b>1998</b> , 98, 1064-70	16.7	90
54	Localization of the thrombin-binding domain on prothrombin fragment 2. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 8932-9	5.4	27
53	Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. <i>Circulation</i> , <b>1998</b> , 97, 544-52	16.7	180
52	Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H <sub>2</sub> O <sub>2</sub> act synergistically to enhance mitochondrial damage. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 30808-17	5.4	58
51	Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 34730-6	5.4	40
50	New antithrombotic agents. <i>Chest</i> , <b>1998</b> , 114, 715S-727S	5.3	24
49	The new heparins. <i>Coronary Artery Disease</i> , <b>1998</b> , 9, 65-74	1.4	2
48	Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. <i>Annals of Internal Medicine</i> , <b>1998</b> , 129, 1006-11	8	153
47	Use of a clinical model for safe management of patients with suspected pulmonary embolism. <i>Annals of Internal Medicine</i> , <b>1998</b> , 129, 997-1005	8	613
46	Characterization of the stress-inducing effects of homocysteine. <i>Biochemical Journal</i> , <b>1998</b> , 332 ( Pt 1), 213-21	3.8	203
45	The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 80, 413-417	7	85
44	Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 657-62	59.2	584
43	Evidence for allosteric linkage between exosites 1 and 2 of thrombin. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 25493-9	5.4	84
42	Low-molecular-weight heparins. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 688-98	59.2	1303
41	A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. <i>Blood</i> , <b>1997</b> , 89, 3236-3242	2.2	146
40	The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. <i>Translational Research</i> , <b>1997</b> , 130, 649-55		42
39	Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. <i>Circulation</i> , <b>1997</b> , 95, 118-24	16.7	42
38	Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 425, 55-66	3.6	13



37	A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 677-81	59.2	983
36	Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 75, 529-535	7	1
35	More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 76, 0902-0908	7	127
34	Interaction of low molecular weight heparin with ketorolac. <i>Translational Research</i> , <b>1996</b> , 127, 583-7		10
33	Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. <i>Circulation</i> , <b>1996</b> , 94, 3026-49	16.7	617
32	Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma. <i>Pediatric Research</i> , <b>1996</b> , 39, 826-30	3.2	25
31	Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 75, 551-554	7	4
30	Activation of blood coagulation by plaque rupture: mechanisms and prevention. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 18B-22B	3	24
29	Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 606-611	7	284
28	Accuracy of clinical assessment of deep-vein thrombosis. <i>Lancet, The</i> , <b>1995</b> , 345, 1326-30	40	556
27	Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. <i>Journal of Vascular and Interventional Radiology</i> , <b>1995</b> , 6, 19S-23S	2.4	20
26	Antithrombotic therapy in patients undergoing coronary angioplasty. <i>Chest</i> , <b>1995</b> , 108, 486S-501S	5.3	34
25	New antithrombotics. <i>Chest</i> , <b>1995</b> , 108, 471S-485S	5.3	33
24	A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. <i>Circulation</i> , <b>1995</b> , 91, 2184-7	16.7	152
23	FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , <b>1995</b> , 60, 144-146	1.8	11
22	New anticoagulant strategies. Current status and future potential. <i>Drugs</i> , <b>1994</b> , 48, 485-97	12.1	33
21	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. <i>Thrombosis and Haemostasis</i> , <b>1994</b> , 71, 300-304	7	106
20	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 443-447	7	6

19	Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 625-630	7	71
18	Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants?. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 69, 418-421	7	17
17	Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. <i>The American Review of Respiratory Disease</i> , <b>1992</b> , 145, 767-70		33
16	Antithrombins: their potential as antithrombotic agents. <i>Annual Review of Medicine</i> , <b>1992</b> , 43, 9-16	17.4	14
15	Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 542-544	7	22
14	The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 68, 064-068	7	39
13	CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 1044-8	11.5	228
12	The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. <i>British Journal of Haematology</i> , <b>1991</b> , 79, 296-301	4.5	13
11	Development and application of assays for elastase-specific fibrinogen fragments. <i>Annals of the New York Academy of Sciences</i> , <b>1991</b> , 624, 154-66	6.5	3
10	Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 65, 541-544	7	9
9	Effect of fibrinogen degradation products and lung ground substance on surfactant function. <i>Neonatology</i> , <b>1990</b> , 57, 325-33	4	26
8	Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. <i>Biochemistry</i> , <b>1990</b> , 29, 8424-9	3.2	252
7	Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. <i>Journal of Clinical Investigation</i> , <b>1990</b> , 86, 385-91	15.9	864
6	Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1988</b> , 85, 7734-8	11.5	357
5	Dysfibrinogenemia in obstructive liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>1987</b> , 6, 967-70	2.8	4
4	Increased neutrophil elastase activity in cigarette smokers. <i>Annals of Internal Medicine</i> , <b>1987</b> , 107, 680-2	8	78
3	Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity. <i>Thrombosis and Haemostasis</i> , <b>1986</b> , 56, 198-201	7	28
2	Ximelagatran: the first oral direct thrombin inhibitor		1

1	Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials	3
---	--	---